Evidence map›Paper›PMID 35225220›Full record

ArticleClinical and experimental rheumatology2022

The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).

David A Isenberg, Hector Chinoy, Mazen M Dimachkie, Frederick W Miller, Lisa G Rider

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David A IsenbergCentre for Rheumatology, Division of Medicine, University College London Hospital, London, UK.
Hector ChinoyNational Institute for Health Research, Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, UK.
Mazen M DimachkieNeuromuscular Division, Neurology Department, The University of Kansas Medical Center, Kansas City, KS, USA.
Frederick W MillerEnvironmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.
Lisa G RiderEnvironmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA. riderl@mail.nih.gov.

Funding

Assessment, Therapy and Prevention Of Autoimmune DiseaseZIAES101081 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$17.6M
Pathogenesis And Genetic/environmental Risk Factors ForZ01ES101074 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MILLER, FREDERICK · 2002 to 2008
$2.7M
Assessment, Therapy and Prevention Of Autoimmune DiseaseZ01ES101081 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MILLER, FREDERICK · 2002 to 2008
$2.2M
Intramural NIH HHS Z01 ES101074Intramural NIH HHS Z01 ES101081
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MyositisHumans

Identifiers

PMID35225220
PMCPMC13135777

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.